Chronic renal failure
Conditions
Interventions
Intervention Administration of vitamin K Administration of 45 mg of menatetrenone orally
Control no administration of vitamin K
Sponsors
Fujita Health University School of Medicine, Department of Nephrology
Nagoyakinenzaidan Kanayama Clinic Shinseikai Daiichi hospital Narumi Clinic Hirabarikinen Clinic Jyuzen Clinic Tokai Clinic Mizuno clinic Mizuhiro Bunin Okehazama Clinic Stytaikai Hospital Oyamada Onsen Hospital Murase Hospital Takasu Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age over 18 years old 2. Able to gain the informed consent
Exclusion criteria
Exclusion criteria: 1. Remaining days are less than one year. 2. Women who are pregnant 3. Intake of vitamin K antagonists 4. Known hypersensitivity against vitamin k 5. History of thrombosis 6. Significant liver dysfunction 7. Inflammatory bowel disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inhibition of vascular calcification. Comparison of the progression of the calcification index between vitamin K administration group and control group. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparison of vitamin K related biomarkers among between vitamin K administration group and control group. 2.Comparison of the change in DEXA between vitamin K administration group and control group. | — |
Countries
Japan
Contacts
Public ContactMidori Hasegawa
Fujita Health University School of Medicine Department of Nephrology
Outcome results
None listed